Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

Allogene Therapeutics, Inc. (ALLO) incurred an adjusted loss (excluding impairment of long-lived asset) of 43 cents per share in fourth-quarter 2023, narrower than the Zacks Consensus Estimate of a loss of 47 cents.Inclusive of impairment charges, the company posted a loss of 51 cents in the fourth quarter. In the year-ago quarter, the company reported a loss of 67 cents. There was no impairment charge recorded in the year-ago period.ALLO recorded revenues of $0.02 million during the quarter, missing the Za ...